Change of LDL and HDL levels in patients with acute coronary syndrome on admission and 3 months after treatment

Bijan Zamani; Behzad Babapour; Nasim Masoudi

doi:10.18203/2349-3933.ijam20160195

Authors

Bijan Zamani Department of Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Behzad Babapour Department of Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Nasim Masoudi General Practitioner, School of Medicine, Ardabil University of Medical sciences, Ardabil, Iran

DOI:

https://doi.org/10.18203/2349-3933.ijam20160195

Keywords:

LDL, HDL, ACS, Hospital, Ardabil

Abstract

Background: The heart ischemic disease has become considerably prevalent worldwide and causes about one-fifth of deaths. Hyperlipidemia is a risk factor for atherosclerosis that includes hypercholesterolemia and hyperlipidemia. The aim of this study was to study the change in the level of LDL and HDL on admission and 3months after treatment in patients with acute coronary syndrome (ACS).

Methods: This is a case-series study that has been done on 180 patients with acute coronary syndrome. 24 hours after admission, the lipid profile was checked for patients and the amounts of LDL and HDL were registered. After drug prescription and three mounts later the levels of LDL and HDL were rechecked and compared.

Results: 64.4% were men and the average age was 54.46 years. 34.44% were with diabetes, 32.7% were with high blood pressure, 46.6% with hyperlipidemia background, and 56.7% with smoking background. Compare the amounts of LDL, cholesterol and triglyceride after three months showed that the levels of them were decreased significantly.

Conclusions: The results of this study showed that after 3 months of treatment, the mean of LDL level was more than the target range (70 mg/dl) that this may be due to inadequate dose of drug, irregular use, improper education to patient and irregular follow-up.

Metrics

Metrics Loading ...

References

Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. Am Fam Physician. 2005;72(1):119-26.

Truelsen T, Mähönen M, Tolonen H, Asplund K, Bonita R, Vanuzzo D, et al. Trends in stroke and coronary heart disease in the who monica Project. Stroke. 2003;34(6):1346-52.

Cannon. American College of Cardiology. Key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. JACC. 2001;38(7):2125-8.

Piranfar MA, Pardal AH, Afshar M, Beyranvand M. Comparing the Serum Level of Apelin in Patients with Lone Atrial Fibrillation and their Control Group. Pajoohandeh Journal. 2010;15(2):83-7.

Braunwald E, Zipes D, Libby P. Heart Disease. 6th Ed, W.B. Saunders Co, Philadelphia, 2001.

McCaig Lf, Burt CW. National hospital Ambulatory Medical Care Survey 2004. Emergency department summary. Adv Data. 2006;(372):1-29.

Justin L. The Increasing Incidence of Coronary Artery Disease and Cardiovascular Risk Factors Among a Southwest Native American Tribe. Intern Med. 2002:162-8.

Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H, et al. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol. 2006;5(15):431-8.

Fitchett D. Assessment of the patient with diabetes for coronary heart disease risk: Review and personal reflection. Can J Diabetes. 2007;31(2):153-63.

Haidari M, Moghadam M, Chinicar M, Ahmadieh A, Doosti M. Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients. Clin Biochem. 2001;34:149-55.

Sakuma I, Kishimoto N, Oyama N, Saijo Y, Nawate S, Souma T, et al. Low high-density lipoprotein cholesterol, hypertension, diabetes, but not high low-density lipoprotein cholesterol as predictors of acute coronary syndrome in northern area of japan: a case-control study. JACC. 2004;13:1047-80.

Hammoudeh AJ, Al-Tarawneh H, Elharassis A, Haddad J, Mahadeen Z, Badran N, et al. Prevalence of conventional risk factors in Jordanians with coronary heart disease: The Jordan hyperlipidemia and related targets study. Int J Cardiol. 2006;110(2):179-83.

Van Wyk JT. Identification of the four conventional cardiovascular disease risk factors by dutch general practitioners. Chest. 2005;128:2521-7.

Radovanovic D, Erne P, Schilling J, Noseda G, Gutzwiller F. Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland: The acute myocardial infarction and unstable angina registry in Switzerland. Heart Drug. 2005;5:131-9.

Rosenson RS, Freeman MW, Rind DM. Statins: Actions, side effects, and administration. 2011; Available from: URL: http://www.uptodate.com/contents/statinsactions-side/.

Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128-33.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. Am J Cardiol. 2003;92(2):152-60.